MX2007010593A - Inhibidores de cyp17/antiandrogenos esteroideos de heteroailo de c-17 novedosos: sintesis, actividades biologicas in vitro, farmacocinetica y actividad antitumoral. - Google Patents

Inhibidores de cyp17/antiandrogenos esteroideos de heteroailo de c-17 novedosos: sintesis, actividades biologicas in vitro, farmacocinetica y actividad antitumoral.

Info

Publication number
MX2007010593A
MX2007010593A MX2007010593A MX2007010593A MX2007010593A MX 2007010593 A MX2007010593 A MX 2007010593A MX 2007010593 A MX2007010593 A MX 2007010593A MX 2007010593 A MX2007010593 A MX 2007010593A MX 2007010593 A MX2007010593 A MX 2007010593A
Authority
MX
Mexico
Prior art keywords
synthesis
antiandrogens
pharmacokinetics
novel
biological activities
Prior art date
Application number
MX2007010593A
Other languages
English (en)
Spanish (es)
Inventor
Angela Brodie
Vincent Njar
Original Assignee
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland filed Critical Univ Maryland
Publication of MX2007010593A publication Critical patent/MX2007010593A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2007010593A 2005-03-02 2006-03-02 Inhibidores de cyp17/antiandrogenos esteroideos de heteroailo de c-17 novedosos: sintesis, actividades biologicas in vitro, farmacocinetica y actividad antitumoral. MX2007010593A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65739005P 2005-03-02 2005-03-02
PCT/US2006/007143 WO2006093993A1 (en) 2005-03-02 2006-03-02 Novel c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity

Publications (1)

Publication Number Publication Date
MX2007010593A true MX2007010593A (es) 2008-02-20

Family

ID=36941503

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007010593A MX2007010593A (es) 2005-03-02 2006-03-02 Inhibidores de cyp17/antiandrogenos esteroideos de heteroailo de c-17 novedosos: sintesis, actividades biologicas in vitro, farmacocinetica y actividad antitumoral.

Country Status (21)

Country Link
US (1) US7875599B2 (enExample)
EP (2) EP2206719B1 (enExample)
JP (2) JP5130453B2 (enExample)
KR (1) KR101380959B1 (enExample)
CN (2) CN101155823A (enExample)
AT (1) ATE482969T1 (enExample)
AU (1) AU2006218711B2 (enExample)
BR (1) BRPI0607523A2 (enExample)
CA (1) CA2599953C (enExample)
DE (1) DE602006017175D1 (enExample)
DK (2) DK1853619T3 (enExample)
EA (1) EA019560B1 (enExample)
ES (2) ES2528055T3 (enExample)
IL (3) IL185608A (enExample)
MX (1) MX2007010593A (enExample)
NZ (1) NZ561571A (enExample)
PL (2) PL2206719T3 (enExample)
PT (2) PT2206719E (enExample)
SI (2) SI1853619T1 (enExample)
WO (1) WO2006093993A1 (enExample)
ZA (1) ZA200708106B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8569275B2 (en) 2002-08-28 2013-10-29 Harbor Therapeutics, Inc. Steroids having 7-oxgen and 17-heteroaryl substitution
SI1853619T1 (sl) 2005-03-02 2011-01-31 Univ Maryland 3-beta-hidroksi-17-(1H-benzmidazol-1-il)androsta-5,16-dien za uporabo pri zdravljenju bolezni prostate
GB2454118B (en) 2007-06-06 2010-06-02 Univ Maryland Hdac inhibitors and hormone targeted drugs for the treatment of cancer
US20110105445A1 (en) * 2008-03-12 2011-05-05 University Of Maryland, Baltimore Androgen receptor inactivation contributes to antitumor efficacy of cyp17 inhibitors in prostate cancer
US20100048912A1 (en) * 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
WO2009120565A2 (en) * 2008-03-25 2009-10-01 University Of Maryland, Baltimore Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
WO2009129208A2 (en) * 2008-04-14 2009-10-22 University Of Maryland, Baltimore Compositions and methods of inducing endoplasmic reticulum stress reponse
WO2010024930A2 (en) 2008-08-28 2010-03-04 President And Fellows Of Harvard College Cortistatin analogues and syntheses therof
AU2009320250A1 (en) * 2008-10-28 2010-06-03 Biomarin Pharmaceutical Inc. Decahydro-1H-indenoquinolinone and decahydro-3H-cyclopentaphenanthridinone CYP17 inhibitors
GB2514957A (en) * 2009-02-05 2014-12-10 Tokai Pharmaceuticals Inc Combination of a 17 alpha-hydroxylase/c17, 20-lyase inhibitor with an additional therapeutic agent
US20110312916A1 (en) * 2009-02-05 2011-12-22 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
US8791095B2 (en) 2009-02-05 2014-07-29 Tokai Pharmaceuticals, Inc. Steroidal CYP17 inhibitors/antiandrogens
RS53384B (sr) 2009-06-26 2014-10-31 Novartis Ag Derivati 1,3-disupstituisanog imidazolidin-2-on kao inhibitori cyp 17
WO2011017534A2 (en) * 2009-08-07 2011-02-10 Tokai Pharmaceuticals, Inc. Treatment of prostate cancer
WO2011059969A2 (en) * 2009-11-13 2011-05-19 Tokai Pharmaceuticals, Inc. Mammalian metabolites of steroids
WO2011066582A1 (en) * 2009-11-30 2011-06-03 Harbor Biosciences, Inc. Anticancer compounds and screening method
JP2013537210A (ja) 2010-09-16 2013-09-30 ノバルティス アーゲー １７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤
BR112013017635A2 (pt) * 2010-12-16 2016-10-11 Biomarin Pharm Inc inibidores de cyp11b, cyp17 e/ou cyp21
JP6002210B2 (ja) 2011-04-28 2016-10-05 ノバルティス アーゲー １７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤
BR112014001440A2 (pt) * 2011-07-18 2017-02-21 Tokai Pharmaceuticals Inc novas composições e métodos para o tratamento de câncer de próstata
EP2793896A4 (en) * 2011-12-22 2015-06-24 Tokai Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR POLYTHERAPY USING P13K / MTOR INHIBITORS
RU2015137617A (ru) * 2013-03-14 2017-04-18 Юниверсити Оф Мэриленд, Балтимор Офис Оф Текнолоджи Трансфер Агенты, подавляющие андрогенные рецепторы, и их применение
WO2014165815A2 (en) 2013-04-04 2014-10-09 University Of Maryland, Baltimore Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity
BR112016002970A2 (pt) 2013-08-12 2017-09-12 Tokai Pharmaceuticals Inc biomarcadores para o tratamento de distúrbios neoplásicos que usa terapias direcionadas ao androgênio
CN110183461A (zh) 2013-12-24 2019-08-30 哈佛学院院长等 皮质抑素类似物及其合成和用途
CN103694299A (zh) * 2014-01-13 2014-04-02 中国药科大学 甾体类雄激素受体抑制剂、其制备方法及其医药用途
WO2016119742A1 (zh) * 2015-01-29 2016-08-04 苏州晶云药物科技有限公司 (3β)-17-(1H-苯并咪唑-1-基)雄甾-5，16-二烯-3-醇的盐及其制备方法
EP3294298A4 (en) 2015-05-08 2018-10-17 President and Fellows of Harvard College Cortistatin analogues, syntheses, and uses thereof
WO2017004411A1 (en) 2015-07-01 2017-01-05 President And Fellows Of Harvard College Cortistatin analogues and syntheses and uses thereof
US10682362B2 (en) 2015-10-14 2020-06-16 Wayne State University Treatments and diagnostics for cancers
WO2018029223A1 (en) * 2016-08-08 2018-02-15 Industriale Chimica S.R.L. PROCESS FOR THE PREPARATION OF 3ß-HYDROXY-17-(1H-BENZIMIDAZOL-1-YL)ANDROSTA-5,16-DIENE
IT201600121375A1 (it) * 2016-11-30 2018-05-30 Ind Chimica Srl PROCESSO PER LA PREPARAZIONE DI 3ß-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE
IT201600083406A1 (it) * 2016-08-08 2018-02-08 Ind Chimica Srl PROCESSO PER LA PREPARAZIONE DI 3β-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE
WO2019160889A1 (en) * 2018-02-13 2019-08-22 Dana-Farber Cancer Institute, Inc. Cyclin-dependent kinase inhibitors and methods of use
EP3752517B1 (en) 2018-02-13 2025-04-09 Dana-Farber Cancer Institute, Inc. Cyclin-dependent kinase degraders and methods of use
US12410194B2 (en) 2019-11-26 2025-09-09 Dana-Farber Cancer Institute, Inc. Potent and selective azaindole inhibitors of CDK8 and CDK19

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA27440A (en) 1887-08-16 James T. Walsh Art of making sheet metal cans, for packing meats, fruits, vegetables, etc.
CH621803A5 (enExample) * 1974-08-08 1981-02-27 Siphar Sa
US5604213A (en) * 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
US5994335A (en) * 1997-10-17 1999-11-30 The University Of Maryland, Baltimore 17-azolyl steroids useful as androgen synthesis inhibitors
BRPI0412989A (pt) 2003-07-29 2006-10-03 Dompe Spa combinação farmacêutica útil para mobilização de célula-tronco
SI1853619T1 (sl) 2005-03-02 2011-01-31 Univ Maryland 3-beta-hidroksi-17-(1H-benzmidazol-1-il)androsta-5,16-dien za uporabo pri zdravljenju bolezni prostate

Also Published As

Publication number Publication date
JP5613206B2 (ja) 2014-10-22
CA2599953A1 (en) 2006-09-08
US7875599B2 (en) 2011-01-25
KR101380959B1 (ko) 2014-04-04
DK1853619T3 (da) 2011-01-10
PT1853619E (pt) 2011-01-03
DK2206719T3 (en) 2015-01-26
EA019560B1 (ru) 2014-04-30
HK1115387A1 (en) 2008-11-28
BRPI0607523A2 (pt) 2009-09-08
EA200701872A1 (ru) 2008-06-30
US20080280864A1 (en) 2008-11-13
KR20070120119A (ko) 2007-12-21
JP5130453B2 (ja) 2013-01-30
IL185608A (en) 2016-06-30
ZA200708106B (en) 2008-12-31
IL210480A0 (en) 2011-03-31
IL185608A0 (en) 2008-01-06
SI2206719T1 (sl) 2015-03-31
ES2353413T3 (es) 2011-03-01
PL1853619T3 (pl) 2011-03-31
PT2206719E (pt) 2015-02-05
AU2006218711A2 (en) 2006-09-08
DE602006017175D1 (de) 2010-11-11
EP2206719B1 (en) 2014-10-22
EP1853619B1 (en) 2010-09-29
CN103349664A (zh) 2013-10-16
EP1853619A1 (en) 2007-11-14
IL210478A0 (en) 2011-03-31
PL2206719T3 (pl) 2015-03-31
IL210480A (en) 2015-06-30
AU2006218711A1 (en) 2006-09-08
NZ561571A (en) 2009-09-25
EP2206719A3 (en) 2011-01-05
WO2006093993A1 (en) 2006-09-08
AU2006218711B2 (en) 2010-11-11
EP1853619A4 (en) 2009-08-26
SI1853619T1 (sl) 2011-01-31
JP2012255026A (ja) 2012-12-27
CN101155823A (zh) 2008-04-02
ATE482969T1 (de) 2010-10-15
EP2206719A2 (en) 2010-07-14
JP2008536807A (ja) 2008-09-11
CA2599953C (en) 2013-08-13
ES2528055T3 (es) 2015-02-03

Similar Documents

Publication Publication Date Title
MX2007010593A (es) Inhibidores de cyp17/antiandrogenos esteroideos de heteroailo de c-17 novedosos: sintesis, actividades biologicas in vitro, farmacocinetica y actividad antitumoral.
WO2009120565A3 (en) Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
AU2010210422A8 (en) Novel prodrugs of steroidal CYP17 inhibitors/antiandrogens
EA017278B9 (ru) Соединения азаиндазола и способы применения
SG141468A1 (en) Novel curcumin analogues and uses thereof
NO2017019I2 (no) Enzalutamid eller et farmasøytisk akseptabelt salt derav
EP2966065A3 (en) Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
ZA200705115B (en) Indazole-carboxamide compounds
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
TW200616615A (en) Compounds and methods for the treatment of cancer
WO2006052889A3 (en) Quinolinone-carboxamide compounds
TW200724537A (en) Pyrimidine derivatives for treatment of hyperproliferative disorders
TW200612925A (en) Prodrug substituted benzoxazoles as estrogenic agents
WO2007048097A3 (en) Anbrosteeone derivatives and method of use thereof
UA95780C2 (en) Xanthine derivatives as selective hm74a agonists
CY1115910T1 (el) ΦΑΡΜΑΚΕΥΤΙΚΗ ΣΥΝΘΕΣΗ ΠΟΥ ΠΕΡΙΛΑΜΒΑΝΕΙ 3-BETA-HYDROXY-17-(l-HBENZIMIDAZOLE-1-YL)ANDROSΤΑ-5,16-DIENE
TW200603812A (en) D-homo-17-chlor-16(17)-ene steroids
WO2007139778A3 (en) Rhamnose substituents of sl0101 and therapeutic uses thereof
WO2005097089A3 (en) Derivatives of leinamycin for use as anticancer agents
TW200634005A (en) Tricyclic amino alcohols, processes for synthesis of same and use of same as anti-inflammatory drugs

Legal Events

Date Code Title Description
FG Grant or registration